Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report.

Date publication

mars 2019

Journal

Annals of translational medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand , Dr BENDER Laura

Tous les auteurs :
Bender L, Meyer G, Quoix E, Mennecier B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31019956

Résumé

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.

Mots clés

Anaplastic lymphoma kinase rearrangement (ALK rearrangement), ceritinib, diffuse interstitial pneumonitis, non-small cell lung cancer (NSCLC)

Référence

Ann Transl Med. 2019 Mar;7(5):106